Retinal PhysicianA Critical Eye on GLP-1 Receptor Agonists

🎓 Expert Commentary / Peer Perspective

At the 2026 Retina World Congress, Rishi P. Singh, MD, of Mass Eye and Ear synthesized evidence across four retinal safety domains for GLP-1 receptor agonists: diabetic retinopathy, AMD, NAION, and retinal vein occlusion. The strongest signal involves early DR worsening during rapid glycemic improvement, not direct retinal drug toxicity.

Clinical Considerations

• SUSTAIN-6 reported a hazard ratio of 1.76 for retinopathy complications within the first 1 to 2 years of semaglutide use, driven by rapid HbA1c reduction in patients with preexisting severe NPDR or proliferative disease
• NAION evidence remains conflicted: one Mass Eye and Ear analysis reported a 4.3-fold higher risk, while multiple large database studies have not consistently reproduced the association
• AMD data conflict across two 2025 studies, with discrepancy potentially attributable to inadequate baseline severity stratification in the study reporting increased neovascular AMD risk
• RVO evidence is the most reassuring: large population-based cohorts show no increased risk and suggest possible reduction in branch RVO incidence

Practice Applications

• Obtain baseline retinal examination before initiating GLP-1 therapy in patients with diabetes
• Monitor more closely during periods of aggressive glycemic improvement in patients with severe NPDR or proliferative DR
• Counsel patients with disc-at-risk anatomy or vascular risk factors on NAION symptoms without recommending therapy discontinuation
• Await FOCUS trial results for long-term semaglutide retinal safety data before revising practice patterns